Chevy Chase Trust Holdings LLC Purchases 29,510 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Chevy Chase Trust Holdings LLC increased its stake in Thermo Fisher Scientific by 12.2%, acquiring an additional 29,510 shares during Q2, bringing its total to 272,082 shares valued at approximately $110.3 million.
• Several institutional investors have also adjusted their holdings in the company, with Brighton Jones LLC raising its stake by 28.9% and other firms increasing their positions, indicating strong institutional interest in the stock.
• Thermo Fisher Scientific reported earnings of $5.36 per share for the last quarter, exceeding analysts' expectations, with revenues of $10.86 billion, and has set earnings guidance for FY 2025 between $22.220-22.840 EPS.

Chevy Chase Trust Holdings LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 272,082 shares of the medical research company's stock after buying an additional 29,510 shares during the quarter. Chevy Chase Trust Holdings LLC owned approximately 0.07% of Thermo Fisher Scientific worth $110,318,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Brighton Jones LLC raised its stake in Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after buying an additional 988 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the period. GAMMA Investing LLC grew its holdings in Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the period. Shepherd Financial Partners LLC lifted its position in Thermo Fisher Scientific by 7.7% during the first quarter. Shepherd Financial Partners LLC now owns 421 shares of the medical research company's stock worth $209,000 after buying an additional 30 shares in the last quarter. Finally, Lion Street Advisors LLC raised its position in Thermo Fisher Scientific by 25.6% in the first quarter. Lion Street Advisors LLC now owns 624 shares of the medical research company's stock valued at $311,000 after purchasing an additional 127 shares during the period. Institutional investors own 89.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Raymond James Financial restated an "outperform" rating and set a $535.00 price objective (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research note on Tuesday. Finally, Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Fifteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $589.10.

Thermo Fisher Scientific Trading Up 1.7%

TMO opened at $536.75 on Friday. The firm's fifty day simple moving average is $494.18 and its 200 day simple moving average is $449.02. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The stock has a market capitalization of $202.68 billion, a P/E ratio of 31.04, a P/E/G ratio of 2.87 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the business posted $5.37 EPS. The business's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 400 shares of the firm's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 over the last three months. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.